Obesity Management Market is expected to register 8.4% CAGR during the forecast period of 2019 to 2025 and is expected to be valued at USD 9.34 Billion in 2025.
The global market for obesity management is expected to grow at a moderate pace during the forecast period, owing to factors such as the increasing number of obese individuals, rising awareness of obesity management, prevalence of lifestyle diseases, and technological advancements for the treatment of obesity.
The increasing number of obese individuals has been the major factor for influencing the growth of the market. According to a study it was found that in 2016, globally, approximately 2 billion adults and teens were overweight. Out of these more than 650 million were obese. More than 39% of adults aged 18 years and above were overweight in same year and 13% were obese. It is also found that in many countries obesity is considered as life-threatening and kills more people than underweight. Thus, the increasing number of obese individuals is considered to be a major factor driving the growth of the market.
Segmentation
The global obesity management market is segmented based on type and region.
The global market for obesity management, by type, is divided into medication and surgery. Moreover, the medication segment is further classified into orlistat, lorcaserin, phentermine and topiramate, bupropion and naltrexone, and liraglutide. Furthermore, the surgery is sub-segmented into laparoscopic adjustable gastric band, gastric sleeve, and gastric bypass.
In the current scope of the study, the segments mentioned above are covered under four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The obesity management market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European obesity management market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The obesity management market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The obesity management market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Some of the Key Players operating in the Global Obesity Management Market are Pfizer Inc. (US), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (UK), AstraZeneca (UK), Herbalife Ltd. (US), Apollo Endosurgery (US), and Ethicon, Inc. (US).
Global Obesity Management Market, by Type
- Medication
- Orlistat
- Lorcaserin
- Phentermine and Topiramate
- Bupropion and Naltrexone
- Liraglutide
- Surgery
- Laparoscopic Adjustable Gastric Band
- Gastric Sleeve
- Gastric Bypass
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization